



2021 Belt and Road Trade and Investment Forum

BRI Vaccine Partnership Initiative

December 2021

BRI Vaccine Partnership Initiative

Key Facts

- Launched at the end of Q2 2021
- 29 countries at launch
- 35% of the world's 2021 population

BRI Vaccine Partnership Initiative

Strategic Rationale

- Despite circa 30 billion doses of COVID vaccine production by Western pharmaceutical companies in 2021/2022, and China now forecast to manufacture circa 10 billion doses in 2021/2022, and the world needing only 17 billion (3 doses/person), many emerging market countries are not receiving adequate doses and when they do receive them sometimes the prices can be very high
- While China is part of COVAX and works with the WHO, it alone cannot manufacture enough doses to immunize the world
- Thus, the BRI Vaccine Partnership was created designed to:
 - License Chinese vaccines to be produced and distributed locally in the countries
 - Goal of making each country vaccine independent by year end 2022
 - Lower the cost of the vaccines (Western companies pricing highly profitable)

BRI Vaccine Partnership Initiative

Evolving Strategies

- Mostly partnerships with domestic labs/pharmaceutical organizations
- Some direct investment by Chinese vaccine companies: Chile and Sri Lanka (new Sinovac manufacturing plants)
- Regional/multi-country: UAE (Serbia, Hungary, Belarus, Philippines?)
- Global partnership: Sino-Innovax Biotech Pte Ltd (Singapore); a global JV between Sinopharm Biotech (Hong Kong) and Innova Bio-Medical Pte Ltd (Singapore), one of the world's largest COVID-19 test providers , controlled by PE firm Pasaca Capital Inc

BRI Vaccine Partnership Initiative

Countries Choosing Multiple Vaccine Production

- Indonesia – China, USA, local
- Thailand – China, UK, Japan
- Vietnam – China, Japan, USA, UK, local
- Morocco – China, Russia

BRI Vaccine Partnership Initiative

Countries not in the original 29

- Egypt
- Hungary
- Serbia
- Belarus

BRI Vaccine Partnership Initiative

Chinese Vaccines International Production – Selected Countries

Country	Population (m)	Partner	Public/Private	Dosages (m)
*Indonesia	276	BioFarma (Sinovac) PT Etama (Walvax)	Public	150 ⁽¹⁾
*Pakistan	220	Searle (Livzon)	Public	36 ⁽²⁾
Egypt	100	VACSERA (Sinovac)	Government	200 ⁽³⁾
Algeria	45	Saidek (Sinovac)	Public	30 ⁽⁴⁾
Morocco	36	Sothema (Sinopharm)	Public	60 ⁽⁵⁾
*Malaysia	33	Pharmaniaga / (Sinovac / Solutions Group)	Public	24 ⁽⁶⁾
*Chile	19	Sinovac	Government	60 ⁽⁷⁾
*UAE	10	Group 42 / (Sinopharm)	Private	24 ⁽⁸⁾

(1) Bridge Consulting (July 2021): 154 million/yr end 2021; 250 million 2022. Walvax still testing September 2021.

(2) Searle/Livzon JV 04/21 initially for 3 million doses/month. CanSino and Walvax being trialled.

(3) Forecast in July 30 million/yr; by September increased to 100 million/yr – if new plant, then multiples (possibly 1 billion doses).

(4) In October; manufacturing would soon increase to 8 million/month with the possibility of 200 million doses/yr in the future.

(5) \$500 million investment to produce and distribute up to 5 million/month – to be exported to Maghrebi and African countries.

(6) Production of 5 million/month in September.

(7) In August, Sinovac, announced its decision to set up its new South American plant in Chile. This plant will have the capacity to produce over 60 million doses/yr once operational in Q2 2022.

(8) 2021 Amounts. 2022 onwards 200 million doses.

THANK YOU